REBLOZYL® (luspatercept-aamt) is a prescription medicine used to
treat anemia (low red blood cells) without previous erythropoiesis
stimulating agent use (ESA-naïve) in adult patients with very low- to
intermediate-risk myelodysplastic syndromes (MDS) who may require regular
red blood cell (RBC) transfusions.
REBLOZYL is not for use as a substitute for RBC transfusions in people who
need immediate treatment for anemia.
It is not known if REBLOZYL is safe or effective in children under 18 years
of age.
INDICATIONS (2 of 3)
REBLOZYL® (luspatercept-aamt) is a prescription medicine used to
treat anemia (low red blood cells) in adults with myelodysplastic syndromes
with ring sideroblasts (MDS-RS) or myelodysplastic/myeloproliferative
neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) who need
regular RBC transfusions and have not responded well to or cannot receive an
erythropoiesis stimulating agent (ESA).
REBLOZYL is not for use as a substitute for RBC transfusions in people who
need immediate treatment for anemia.
It is not known if REBLOZYL is safe or effective in children under 18 years
of age.
INDICATIONS (3 of 3)
REBLOZYL® (luspatercept-aamt) is a prescription medicine used to
treat anemia (low red blood cells) in adults with beta thalassemia who need
regular red blood cell (RBC) transfusions.
REBLOZYL is not for use as a substitute for RBC transfusions in people who
need immediate treatment for anemia.
It is not known if REBLOZYL is safe or effective in children.
